Roche struck a research and license deal with Manifold Bio to develop next‑generation 'brain shuttles' aimed at improving delivery of biologics across the blood‑brain barrier. The agreement, structured to include upfront payments and potential milestones worth up to $2 billion, gives Roche access to Manifold’s platform to support neurology programs as Roche advances late‑stage assets. The pact signals renewed industry investment in transport technologies to address CNS delivery bottlenecks.